Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2-ferrocenylethyl)maleimide is an organometallic small molecule that combines a ferrocenyl group with a maleimide moiety. The compound features both the redox-active ferrocene and the electrophilic maleimide, which is reactive toward thiols and amines due to its 2,5-pyrroledione structure. This dual functionality makes it valuable in chemical biology and materials science. It can covalently modify thiol-containing biomolecules (such as cysteine residues in proteins or glutathione), potentially affecting cellular redox states and signaling pathways. Its electroactive properties have led to research interest in its use as a probe for protein labeling/derivatization (notably in analytical chemistry), as well as potential anticancer or therapeutic applications[1][2][3][6]. However, it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2-ferrocenylethyl)maleimide.